Emergent BioSolutions Inc.

Is Emergent BioSolutions publicly traded?

Yes. It trades on the New York Stock Exchange under the ticker EBS. It has no controlling shareholder, with ownership dispersed among institutional and retail investors.

Who owns Emergent BioSolutions?

No single owner controls it. It is a public company whose shares are held primarily by institutional investors, with founder Fuad El-Hibri's influence ended by his 2022 death.

What does Emergent BioSolutions make?

Its two core businesses are naloxone products (Narcan and KLOXXADO nasal sprays for opioid overdose) and medical countermeasures for anthrax, smallpox, botulism, and Ebola sold to governments.

Who founded Emergent BioSolutions?

Fuad El-Hibri founded the company in 1998 as BioPort, built around the anthrax vaccine licensed from a former Michigan state facility, and renamed it Emergent BioSolutions in 2004.

What is Emergent's market position?

It is a niche specialty pharma leader: the branded leader in naloxone and a primary supplier of US biodefense countermeasures, with FY2025 revenue of $742.9 million.

What was Emergent's biggest controversy?

The 2021 COVID-19 vaccine manufacturing failure at its Baltimore plant, which destroyed millions of doses, triggered FDA action and congressional scrutiny, and led to its exit from contract manufacturing.

Does Emergent own Narcan?

Yes. Emergent acquired Narcan through its October 2018 purchase of Adapt Pharma for up to $735 million and markets it as its flagship commercial product.

Emergent's roots are unusual for a pharma company. Fuad El-Hibri founded the business in 1998 as BioPort, acquiring the Michigan Biologic Products Institute in Lansing, a former state-owned facility that held the license for the only FDA-approved anthrax vaccine, BioThrax. That single asset, sold almost exclusively to the US military, was the company's foundation.

Renamed Emergent BioSolutions in 2004, the company went public on the NYSE in 2006 and spent the next decade expanding its government countermeasure franchise. Acquisitions added smallpox vaccine ACAM2000, botulism antitoxin BAT, and other stockpile products, while contract development and manufacturing services grew into a significant secondary business.

Two moves defined the company's next phase. In October 2018 Emergent acquired Adapt Pharma for up to $735 million, gaining Narcan, the first FDA-approved naloxone nasal spray, and pivoting into branded commercial pharmaceuticals. Then the COVID-19 pandemic made it a major contract manufacturer for Johnson & Johnson and AstraZeneca vaccines at its Baltimore Bayview plant.

That pandemic moment ended badly. In 2021 a manufacturing cross-contamination incident at Bayview ruined tens of millions of vaccine doses, triggered congressional scrutiny, an FDA warning letter, executive departures, and a shareholder wipeout as the stock collapsed from its highs. Founder El-Hibri died in 2022 amid the fallout.

Under CEO Joe Papa, hired in 2021, Emergent restructured aggressively: it exited the troubled CDMO business, divested non-core assets, cut staff, paid down more than $110 million of debt in 2025 alone, and refocused on its profitable naloxone and MCM franchises. The strategy worked financially. FY2025 produced $52.6 million in net income against a $190.6 million loss the year before, with adjusted EBITDA rising to $205 million.

The company's current chapter pairs a stabilized government biodefense business with a consumer health product, Narcan, that became the first OTC naloxone spray in March 2023 and has shipped more than 100 million doses since 2016.

Emergent's stated mission of protecting public health gives its business model an inherently social dimension: its products are used by first responders, public health agencies, and militaries specifically to save lives during emergencies.

The company publishes ESG reporting covering governance, employee safety, and product quality, and its post-2021 restructuring placed heavy emphasis on quality system remediation after the FDA findings at Bayview. On the specific issue of opioid-crisis responsibility, Emergent positions itself on the response side of the epidemic as an overdose-reversal supplier, though critics have argued that profiting from naloxone sales sits uneasily beside the industry's broader opioid history, a tension the company addresses through donation and public-interest pricing programs.

Emergent's defining controversy is the 2021 COVID-19 vaccine manufacturing failure at its Baltimore Bayview facility. Cross-contamination between Johnson & Johnson and AstraZeneca vaccine materials destroyed tens of millions of doses, prompted an FDA inspection and warning letter, congressional hearings, and a Justice Department investigation. The episode cost the company its reputation for manufacturing reliability, triggered executive departures, and led to its exit from contract manufacturing.

Earlier scrutiny focused on its relationship with government: critics long questioned the company's heavy spending on lobbying and its success in maintaining the anthrax vaccine in the stockpile despite doubts about the product. Founder El-Hibri's political donations drew periodic media attention.

More recently, Narcan's pricing has drawn criticism from public health advocates who argue the roughly $45 OTC price is too high for the communities most affected by overdoses. The company has responded with public-interest pricing and donation programs, but the tension between a for-profit model and a public health product remains an active debate.